FIELD: molecular virology.
SUBSTANCE: invention relates to the field of molecular virology, biotechnology and medicine, in particular to the production of a chimeric protein that spontaneously forms in vitro virus-like particles (VLP) containing the protein VP1 Echovirus 30 (ECHO30). The obtained virus-like norovirus particles containing the protein VP1 of the enterovirus Echovirus 30 on their surface can be used to prepare vaccines against non-polio enteroviruses. The method for obtaining virus-like particles of norovirus containing the protein VP1 Echovirus 30 (ECHO30) in vitro includes cultivation of E. coli cells transformed by chimeric protein in a suitable culture medium, isolation and purification of virus-like particles. In this case, a chimeric protein SN-VP1E30 is created with a size of 516 amino acids with a molecular weight of 57 kDa, with a structure in accordance with the sequence SEQ ID NO: 1 and the transformation of E. coli cells, Rosette strain 2 (DE3) with a plasmid containing a nucleotide sequence encoding the amino acid sequence SEQ ID NO: 1.
EFFECT: implementation of the invention provides for the creation of a chimeric protein SN-VP1E30 with a size of 516 amino acids with a molecular weight of 57 kDa, which is capable of spontaneously assembling into VLP presenting antigenic determinants of the protein VP1 of enterovirus E30.
1 cl, 4 dwg, 6 ex
Title | Year | Author | Number |
---|---|---|---|
VIRUS-LIKE PARTICLES WITH HIGH-DENSITY COATING FOR INDUCTION OF ANTIBODY EXPRESSION | 2017 |
|
RU2813282C2 |
CHIMERIC PROTEIN L1 OF PAPILLOMAVIRUS | 2020 |
|
RU2808002C2 |
ISOLATED MODIFIED VP1 CAPSID PROTEIN OF ADENO-ASSOCIATED VIRUS OF SEROTYPE 5 (AAV5), CAPSID AND VECTOR BASED ON IT | 2019 |
|
RU2751592C2 |
POLYVALENT IMMUNOGENIC COMPOSITION AGAINST HUMAN PAPILLOMAVIRUS | 2020 |
|
RU2806424C2 |
FMDV-E2 FUSION PROTEINS AND USE THEREOF | 2016 |
|
RU2714428C2 |
CODON-OPTIMIZED NUCLEIC ACID WHICH ENCODES SMN1 PROTEIN, AND USE THEREOF | 2020 |
|
RU2742837C1 |
ISOLATED MODIFIED VPI CAPSID PROTEIN OF ADENO-ASSOCIATED VIRUS OF SEROTYPE 9 (AAV9), CAPSID AND VECTOR BASED THEREON | 2021 |
|
RU2825667C2 |
VACCINE BASED ON AAV5 FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-CoV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2020 |
|
RU2783313C1 |
FMDV RECOMBINANT VACCINES AND USE THEREOF | 2015 |
|
RU2745373C2 |
VACCINES BASED ON VIRUS-LIKE PARTICLES (VLP) OF CANINE PARVOVIRUS (CPV) AND APPLICATION THEREOF | 2016 |
|
RU2710854C1 |
Authors
Dates
2023-02-01—Published
2022-02-03—Filed